Barely Significant
← all excerpts

Impact of Central Event Adjudication on the PLATO Trial Results.

Rev Cardiovasc Med · 2025 · PMC12059727 · PMID 40351676

Europe PMCDOI
1
hedged sentence
0.0190
closest p · 0.4× alpha
0.0190
boldest claim

The sentences

highly significantp = 0.019actually significant
The primary endpoint in the PLATO trial exhibited highly significant disagreement favoring ticagrelor for vascular death (HR = 2.02; 95% CI: 1.1–3.64; p = 0.019); MI (HR = 2.31; 95% CI: 2.79–43.94; p = 0.034); stroke (HR = 1.37; 95% CI: 2.66–63.28; p = 0.036); total events (HR = 2.51; 95% CI: 1.86–3.39; p = 0.01).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.